Despite the concerns about the potential carcinogenic effect of GLP‐1 RA found in preliminary and in vitro studies [71, 72, 73], recent MAs have demonstrated that tirzepatide and semaglutide were not associated with an increased risk of any type of cancer [74, 75]. This evidence concerns the gene GLP1R and cancer.